Latest research on Desvenlafaxine

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Desvenlafaxine side effects

In the present study, it was seen that Desvenlafaxine produced a decrease from the baseline value of HAM-D from 3 weeks onward till the end of the study, that is, at 6 weeks. [source, 2016]
Desvenlafaxine has also been shown to cause a significant reduction in depression in several studies. [source, 2016]
In the present study, it was seen that Desvenlafaxine also produced a decrease from the baseline value of HAM-A, from 3 weeks onward till the end of the study, that is, at 6 weeks. [source, 2016]
In the present study, it was seen that Desvenlafaxine also produced a decrease from the respective baseline value of CGI from 3 weeks onward till the end of the study, that is, at 6 weeks. [source, 2016]
UKU scale is used to evaluate side effects and the values are (0.93 and 1.13), respectively in Escitalopram and Desvenlafaxine group. [source, 2016]
Similar side effect profile was put forth by Soares et al.,[14] who showed both Desvenlafaxine and Escitalopram were generally safe and well-tolerated. [source, 2016]
Similarly a trial of Escitalopram (started with 5 mg for a week, then increased to 10 mg/day) and Desvenlafaxine sustained release (started with 25 mg/day for a week, then increased to 50 mg/day) was also given for three weeks each, but no improvement was observed. [source, 2015]
In one open-label study, LDX administered in combination with Venlafaxine extended release (VXR), which is metabolized by CYP2D6 and CYP3A4 [4], was associated with small increases in VXR exposure, small decreases in exposure to the primary VXR metabolite (O-desmethylVenlafaxine [ODV]), and no change in composite VXR + ODV exposure when compared with VXR alone in healthy volunteers [10]. [source, 2015]
Above all, although several statistically significant side effects were identified, a wrong conclusion was made by stating that Desvenlafaxine appears safe (34). [source, 2014]
The meta-analysis of awakenings per night because of hot flashes and the change in the GCS, total score have brought additional evidence to support Desvenlafaxine effectiveness in the treatment of hot flashes. [source, 2014]